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delivery device into a mammal in need of treatment is also
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The systemic toxicity of cyclosporine A may be mini

IMPLANTABLE CONTROLLED RELEASE
DEVICE TO DELIVER DRUGS DIRECTLY
TO AN INTERNAL PORTION OF THE BODY

miZed by delivering the drug locally. Although direct intra
vitreal injection prevents experimental autoimmune uveitis
(EAU), repeated injection is not a practical mode of admin

TECHNICAL FIELD

istration.
Due to the risks that certain drugs impose, researchers

The present invention relates to a simple and implantable
sustained release drug delivery device With an inner core
containing an effective amount of a loW solubility agent

covered by a non-bioerodible polymer coating layer that is
permeable to the loW solubility agent. Also, the polymer
coating layer holds the drug in the correct anatomic position
and essentially prevents disintegration of the drug core While

have developed systems for administering such drugs to aid
in the treatment of ailments and diseases. The systems have
been designed largely to reduce and to control the release
10

rate of incorporated drugs. HoWever, these systems fail to
achieve the surprising and unexpected results obtained by
the present invention.

not signi?cantly impairing the drug release rate. A method

For example, US. Pat. No. 5,091,185 to Castillo et al.

for treating a mammal to obtain a desired local or systemic

relates to implantable pellets for veterinary use comprising

physiological or pharmacological effect by surgically

15 a bioactive material such as somatotropin coated With a

implanting the device into a mammal in need of treatment is
also disclosed.

polyvinyl alcohol polymer to prolong the release of the
bioactive material after implantation. Parenteral administra
tion of the coated pellet is by subcutaneous implantation and
may be accomplished surgically or by injecting small pellets

BACKGROUND
Uveitis is a disease of the eye Which can be located

20

throughout the eye including the posterior and anterior
chambers of the eye as Well as the vitreous body. Uveitis, the
in?ammation of the uvea, is responsible for about 10% of
the visual impairment in the United States.
Panuveitis refers to in?ammation of the entire uveal

25

(vascular) layer of the eye. Posterior uveitis generally refers

patent.

to chorioretinitis and anterior uveitis refers to iridocyclitis.

U.S. Pat. No. 4,300,557 to Refojo et al. relates to an

The in?ammatory products, that is, cells, ?brin, excess
protein, of these in?ammations are commonly found in the
?uid spaces of the eye including the anterior chamber,
posterior chamber and vitreous space as Well as the tissue
involved in the in?ammatory response. Uveitis may occur
folloWing surgical or traumatic injury to the eye, as a
component of an autoimmune disorder such as rheumatoid

arthritis, Behcet’s disease, ankylosing spondylitis,

through a needle. HoWever, the Castillo patent does not
teach that the polyvinyl alcohol polymer should be heated to
temperatures greater than about 100° C. to induce changes
in the crystal structure of the polymer to render it non
erodible. Somatotropins are heat sensitive and rapidly
decompose on heating above 100° C. so such heating Would
be impractical for the systems described in the Castillo

30

improved process for dispensing a lipid-soluble, labile drug
by diffusion from an implantable silicon capsule to a site

Within an animal body being treated With the drug, Wherein

35

the silicon capsule is provided With a tube sealed at its distal
end and through the interior Wall of Which is cut a longitu
dinal slit of 1 to 1.5 mm for ?lling the capsule folloWing

implantation. The capsule is surgically implanted near the

sarcoidosis, as an isolated immune mediated ocular disorder,

site being treated so that the tube is accessible for ?lling

i.e., pars planitis, iridodyclitis etc., unassociated With knoWn
etiologies, and folloWing certain systemic diseases Which

Without further surgical procedures. In another aspect of the

cause antibody-antigen complexes to be deposited in uveal
tissues. Together these disorders represent non-infectious

invention, a drug is dispensed at a constant rate through an
40

uveitities.
Cyclosporine A, a 1.2 kd cyclic peptide Which is essen

tially insoluble in Water effectively inhibits the development
of experimentally induced uveitis. In human trials, cyclospo

an intraocular site Within an animal body.
U.S. Pat. No. 4,649,047 to KasWan relates to a method for

the treatment of, for example, uveitis occurring throughout
the globe of the eye, by topical administration of cyclospo
45

rine A has been shoWn to be effective in treating chronic

rine to the eye.
U.S. Pat. No. 4,923,699 to Kaufman discloses an eye

treatment system Wherein three dimensional particles of

uveitis, especially that associated With Behcet’s disease.

Unfortunately, systemic therapy With cyclosporine A has
serious draWbacks. Cyclosporine A used systemically has
also been associated With a high incidence of renal toxicity,

expandable, silicon microballoon implanted periocularly to

50

bioerodible material of a speci?c siZe Which are suspended
in a liquid carrier or ointment carrier having a pH acceptable
to the eye are delivered topically to the eye. Various agents

some cases of hepatotoxicity, hypertension, and an increased

may be added to increase viscosity, promote suspension

incidence of opportunistic infections. The systemic side

and/or improve ocular compatibility.

effects of cyclosporine A are so severe and so common that
its use to treat life-threatening or in some cases severe

U.S. Pat. No. 3,832,252 to Higuchi et al. relates to a drug
delivery device comprising an inner solid matrix With solid

sight-threatening disease is not recommended. The systemic
toxicity is such that the National Eye Institute has recom
mended that, for uveitis in?icting one eye, cyclosporine
should not be administered. Finally, a systemic application
of cyclosporine A is limited by its prohibitive cost. Also, it
should be noted that because of poor ocular availability,
topical delivery does not result in the obtention of therapeu
tic levels of the drug in the back of the eye.
Accordingly, there exists a strong need for the elimination
of the undesirable physiological and economic problems
associated With cyclosporine A treatment of uveitis, While

maintaining the advantageous therapeutic properties of this
treatment.

55

particles of drug dispersed therethrough. Any solid material
chemically compatible With the drug and permeable to
passage of the drug by diffusion can be employed.
U.S. Pat. No. 4,309,996 to TheeuWes relates to a system

comprising a microporous diffuser for delivering a bene?cial
60 agent to a ?uid environment of use at a Zero order rate for

an increased length of time at that rate. The system consists

essentially of a microporous Wall, or a part microporous part
semi-permeable Wall, surrounding a compartment having a
space containing the agent separated by a partition from a
65

space containing an expandable entity.
U.S. Pat. No. 4,309,776 to Berguer relates to an intravas

cular implantation device having a chamber for containing

5,773,019
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transplanted cells that is implanted in a Wall of a blood

trans retinoic acid, cis retinoic acid and other related retinoid

vessel or to be implanted betWeen an artery and a vein in a

compounds in the eye.
The above and other objects of the invention Will become

Wall of each for the purpose of introducing hormonal
components into the bloodstream of a human being. It is
disclosed that the material of Which the chamber-forming

readily apparent to those of skill in the relevant art from the

folloWing detailed description and ?gures, Wherein only the

device is made must be tolerated in a blood vessel Without

preferred embodiments of the invention are shoWn and

causing thrombosis and should permit the choice of various

degrees of porosity.
US. Pat. No. 4,973,304 to Graham et al. relates to devices
Which have use in medical or veterinary application as
implants or as inserts. The devices can be implanted surgi

10

the invention.

cally into the body or introduced into a body cavity of a
human patient or an animal such that the active substance

diffuses out of the device through hydrogel WindoWs into the
surrounding body region. The device may be in the form of
a tube of Water-permeable material having at least one port
in the tube Wall.
The above described systems and devices are intended to

BRIEF DESCRIPTION OF DRAWINGS
15

20

certain physiological or pharmacological effects. HoWever,

sustained release drug delivery device shoWing inner drug
core, permeable polymer coating of the present invention
and an extension of the polymer coating layer as a means for
attachment.
FIG. 3 is an enlarged vieW of an embodiment of the

there are many disadvantages associated With their use. The

need for a better release system is especially signi?cant in
the treatment of uveitis. Thus, there remains a long-felt need
in the art for an improved device for providing sustained

FIG. 1 is an enlarged vieW of an embodiment of the

sustained release drug delivery device shoWing inner drug
core and permeable polymer coating.
FIG. 2 is an enlarged vieW of an embodiment of the

provide sustained release of drugs effective in treating
patients at a desired local or systemic level for obtaining

described, simply by Way of illustration of the best mode of
carrying out the invention. As is readily recogniZed the
invention is capable of modi?cations Within the skill of the
relevant art Without departing from the spirit and scope of

sustained release drug delivery device shoWing inner drug
25

release of a drug to a patient to obtain a desired local or

systemic physiological or pharmacological effect.

core, permeable polymer coating layer and an extension of
the polymer coating layer containing a support ring as a
means for attachment Wherein the support ring alloWs
enough space for a suture to be passed betWeen the drug core

DISCLOSURE OF THE INVENTION

and the support ring.

Therefore, it is an object of this invention to provide a
device suitable for the controlled and sustained release of a
composition effective in obtaining a desired local or sys

FIG. 4 is an enlarged vieW of an embodiment of the

sustained release drug delivery device shoWing inner drug
core, permeable polymer coating layer and an extension of
the polymer coating layer containing a support ring as a

temic physiological or pharmacological effect and Which,
once implanted, gives a continuous release to an affected

means for attachment Wherein the support ring forms a loop
through Which a suture can be passed.
FIG. 5 is an enlarged vieW of an embodiment of the

area Without requiring additional invasions into the region.
Moreover, the present invention is designed to hold the loW
solubility agent in the correct anatomic location and to
prevent disintegration of the inner core. By maintaining
surface area, the present invention reduces ?uctuations in

sustained release drug delivery device shoWing inner drug

release characteristics. In one embodiment, ?uctuations

core, permeable polymer coating layer and an extension of
the polymer coating layer containing a backing material as

caused by changes in the composition of the bathing ?uid are

a means for attachment.

also eliminated.

FIG. 6 is an enlarged vieW of an embodiment of the

In one embodiment, the device includes an inner core

sustained release drug delivery device shoWing inner drug

comprising an effective amount of a loW solubility agent,

core, permeable polymer coating layer and an extension of
the polymer coating layer containing a backing material as

and a non-erodible polymer coating layer, the polymer layer
being permeable to the loW solubility agent, Wherein the
polymer coating layer partially or completely covers the

a means for attachment.

FIG. 7 shoWs a graph indicating that 0.5% albumin
uncoated retinoic acid pellets release signi?cantly faster than

inner core.

Another object of the present invention is to provide a
method for treating a mammal, e.g., a human, to obtain a

desired local or systemic physiological or pharmacological
effect. The method includes securing the sustained release
drug delivery device at an area Where release of the agent is

desired and alloWing the agent to pass through the polymer
coating layer to the desired area of treatment.
A further object of the invention is to provide an ocular
device suitable for direct implantation into the eye. Such
devices of the present invention are surprisingly found to
provide sustained release controlled release of various com
positions to treat the eye Without risk of detrimental side
effects.

55

FIG. 12 shoWs tissue levels of cyclosporine folloWing
60

an ocular delivery system that could be applied to an
intraocular lens to prevent in?ammation or posterior capsu

Another object of the present invention is to provide a
means of achieving and maintaining therapeutic levels of

device implantation measured over 6 months. Note rela

tively high levels in the lens. Bars represent SEM.
FIG. 13 shoWs ERG data demonstrating decrease in
scotopic b-Wave amplitude. Data represented as the ratio
b-Wave amplitude in drug eye to b-Wave amplitude in

An additional object of the present invention is to provide

lar opaci?cation.

retinoic acid in the devices according to the invention.
FIG. 8 shoWs clearance of cyclosporine from the vitreous
folloWing a 1 pg injection.
FIG. 9 shoWs clearance of cyclosporine from the vitreous
folloWing a 10 pg injection.
FIG. 10 shoWs tissue levels of cyclosporine folloWing a
10 pg injection into the midvitreous.
FIG. 11 shoWs vitreous concentration of cyclosporine
folloWing device implantation measured over 6 months.

65

control eye. Bars represent SEM.
FIG. 14 shoWs ERG data demonstrating recovery of ERG

folloWing removal of the sustained release device containing

5,773,019
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cyclosporine. Data represented as the ratio b-Wave ampli
tude in drug eye to b-Wave amplitude in control eye. Bars
represent SEM.

prolonged period. Suitable polymers useful in the present
invention include polyvinyl alcohol, ethylene vinyl acetate,

FIG. 15 shows ERG data in the monkey over 6 months
demonstrates no evidence of retinal toxicity. Bars represent
SEM.

polycarbonate, cellulose, cellulose acetate, polyglycolic

silicone, polylactic acid, nylon, polypropylene,
acid, polylactic glycolic acid, cellulose esters or polyether
sulfone. The polymer coating layer is non-bioerodible and is
permeable to the loW solubility agent Without being release
rate limiting.

DESCRIPTION OF THE INVENTION

The present inventors have surprisingly and unexpectedly
discovered a device that is suitable for the controlled and
sustained release of an agent effective in obtaining a desired

10

local or systemic physiological or pharmacological effect.
The device includes an inner core comprising an effective
amount of a loW solubility agent, and a non-bioerodible

polymer coating layer, the polymer layer permeable to the
loW solubility agent, Wherein the polymer coating layer
covers the inner core.

Once implanted, the device gives a continuous supply of
the agent to internal regions of the body Without requiring
additional invasive penetrations into these regions. Instead,

The non-bioerodible polymer coating layer of the present
invention may completely or partially cover the inner core.

the device remains in the body and serves as a continuous
source of the agent to the affected area. In another

embodiment, the device further comprises a means for
attachment, such as an extension of the non-erodible poly
mer coating layer, a backing member, or a support ring. In
a preferred embodiment, the device is suitable for direct

In this regard, any portion of the surface area of the inner
core up to and including 100% may be coated With the

polymer coating layer as long as the pellet is protected
25

The method for treating a mammal to obtain a desired

local or systemic physiological or pharmacological effect

includes surgically implanting the sustained release drug

speci?c period of months (e.g., 3 months, 6 months) or years
(e.g., 1 year, 5 years, 10 years, 20 years) until the agent is
substantially used up.
Suitable loW solubility agents useful in the present inven

delivery device of the present invention into the mammal
and alloWing agent to pass through the device to come in
direct contact With the mammal.
35

intramuscular, intraperitoneal, intranasal, dermal, and the
40

administered at one time or more than one agent may be

The drug delivery device of the present invention is
particularly suitable for direct surgical implantation into the

anti-cancer agents such as BCNU, nonsteroidal anti
45

codrugs including loW solubility codrugs of salts or conju
gates of synergistic pharmacological agents such as suramin/
amiloride or 5-FU/THS, and combinations thereof. The

compounds that may be employed in the practice of the
present invention should be in loW solubility form. Refer

eye.
The entire structure is made of material Which is com
patible With the human tissue With Which it comes in contact.
In a preferred embodiment the material of the device is
polyvinyl alcohol. If a backing member is present in a

preferred embodiment, the backing member may be com

posed of any material tolerated by the human body, prefer

ence may be made to any standard pharmaceutical textbook
for the procedures to obtain a loW solubility form of a drug.

Material that may be suitable for fabricating the polymer
coating layer of the device include naturally occurring or
synthetic materials that are biologically compatible With
bodily ?uids and eye tissues, and essentially insoluble in

like. In addition, one or more of the devices may be

included in the inner core.

analogues), anti-viral agents including high molecular
Weight loW (10-mers) loW solubility anti-sense compounds,
in?ammatory agents such as indomethacin and ?urbiprofen,

The drug delivery device of the present invention may be
administered to a mammal via any route of administration
knoWn in the art. Such routes of administration include

intraocular, intraarticular, subcutaneous, vaginal,

trihydroxy steroid, anti-parasitic agents such as atovaquone,
anti-glaucoma agents such as ethacrynic acid, antibiotics
including cipro?oxacin, differentiation modulators such as
retinoids (e.g., trans-retinoic acid, cis-retinoic acid and

against disintegration, prevented from being physically dis
placed from its required site, and as long as the polymer
coating layer does not adversely retard the release rate.

implantation into the vitreous of the eye.
The device according to the present invention permits
prolonged constant release of loW solubility agents over a

tion include immune response modi?ers such as cyclospo
rine A and FK 506, corticosteroids such as dexamethasone
and triamcinolone acetonide, angiostatic steroids such as

The cyclosporines Which are useful in the practice of the
present invention may be both natural or synthetic cyclospo
rines. For example, cyclosporine A may be used in the
practice of the present invention. Other forms of cyclospo
rines (e.g., isomers) may also be used. Mixtures of at least
tWo different cyclosporines may be used. The only require
ment is that the cyclosporine possess the required activity
vis-a-vis uveitis and is of extremely loW solubility.
This device enables a large variety of drugs and other
agents to be delivered into any internal region of the body,
preferably the eye. Cyclosporine A in loW solubility form is
a preferred drug used in the delivery device.

ably ethylene vinyl acetate, Te?on, silicone, silastic and

nylon.
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These methods of administration and technique for their
preparation are Well knoWn by those of ordinary skill in the
art. Techniques for their preparation are set forth in Rem

bodily ?uids With Which the material Will come in contact.

ington’s Pharmaceutical Sciences.

In addition, the suitable materials essentially prevent inter
action betWeen the loW solubility agent in the inner core of

The drug delivery device may be administered for a
su?icient period of time and under conditions to alloW

the device and proteinaceous components in the bodily ?uid.

treatment of the disease state of concern.

The use of rapidly dissolving materials or materials highly
soluble in eye ?uids or Which permit interaction betWeen the
loW solubility agent in the inner core and proteinaceous
components in the bodily ?uids are to be avoided since
dissolution of the Wall or interaction With the proteinaceous
components Would affect the constancy of drug release, as
Well as the capability of the device to remain in place for a

For localiZed drug delivery, the device may be surgically
implanted at or near the site of action. This is the case for
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devices of the present invention used in treating ocular
conditions, primary tumors, rheumatic and arthritic
conditions, and chronic pain. The device may be used to
control the rate of drug delivery to any internal region of the

body.

